HUP0303563A2 - Ösztrogén receptor modulátorok - Google Patents

Ösztrogén receptor modulátorok

Info

Publication number
HUP0303563A2
HUP0303563A2 HU0303563A HUP0303563A HUP0303563A2 HU P0303563 A2 HUP0303563 A2 HU P0303563A2 HU 0303563 A HU0303563 A HU 0303563A HU P0303563 A HUP0303563 A HU P0303563A HU P0303563 A2 HUP0303563 A2 HU P0303563A2
Authority
HU
Hungary
Prior art keywords
estrogen receptor
compounds
receptor modulators
uterine
estrogen
Prior art date
Application number
HU0303563A
Other languages
English (en)
Hungarian (hu)
Inventor
Helen Y. Chen
Frank P. Dininno
Seongkon Kim
Jane Y. Wu
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0303563A2 publication Critical patent/HUP0303563A2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0303563A 2000-10-19 2001-10-15 Ösztrogén receptor modulátorok HUP0303563A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19
PCT/US2001/042735 WO2002032377A2 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
HUP0303563A2 true HUP0303563A2 (hu) 2004-03-01

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303563A HUP0303563A2 (hu) 2000-10-19 2001-10-15 Ösztrogén receptor modulátorok

Country Status (20)

Country Link
EP (1) EP1333827A2 (sk)
JP (1) JP2004511502A (sk)
KR (1) KR20030042020A (sk)
CN (1) CN1469743A (sk)
AU (2) AU3238102A (sk)
BG (1) BG107676A (sk)
BR (1) BR0114689A (sk)
CA (1) CA2424729A1 (sk)
EA (1) EA200300474A1 (sk)
EC (1) ECSP034558A (sk)
EE (1) EE200300153A (sk)
HU (1) HUP0303563A2 (sk)
IL (1) IL154984A0 (sk)
IS (1) IS6761A (sk)
MX (1) MXPA03003485A (sk)
NO (1) NO20031737L (sk)
PE (1) PE20021083A1 (sk)
PL (1) PL361053A1 (sk)
SK (1) SK4772003A3 (sk)
WO (1) WO2002032377A2 (sk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
PT1501819E (pt) 2002-04-24 2010-11-11 Merck Sharp & Dohme Moduladores dos receptores de estrogéneo
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP2314295B1 (en) 2005-07-29 2015-01-28 Resverlogix, Inc Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8163770B2 (en) * 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
BRPI1009315B8 (pt) 2009-03-18 2021-05-25 Resverlogix Corp composto anti-flamatórios e suas composições farmacêuticas
TR201818390T4 (tr) 2009-04-22 2019-01-21 Resverlogix Corp Yeni̇ anti̇-i̇nflamatuvar ajanlar
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
PL2773354T3 (pl) 2011-11-01 2019-12-31 Resverlogix Corp. Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
AU2002232381B2 (en) 2004-11-18
MXPA03003485A (es) 2003-07-14
IS6761A (is) 2003-03-27
EP1333827A2 (en) 2003-08-13
NO20031737D0 (no) 2003-04-15
PL361053A1 (en) 2004-09-20
WO2002032377A2 (en) 2002-04-25
CN1469743A (zh) 2004-01-21
CA2424729A1 (en) 2002-04-25
SK4772003A3 (en) 2003-08-05
KR20030042020A (ko) 2003-05-27
AU3238102A (en) 2002-04-29
EA200300474A1 (ru) 2003-10-30
PE20021083A1 (es) 2002-12-16
ECSP034558A (es) 2003-06-25
WO2002032377A3 (en) 2002-08-22
EE200300153A (et) 2003-06-16
BG107676A (bg) 2003-11-28
JP2004511502A (ja) 2004-04-15
BR0114689A (pt) 2003-07-01
NO20031737L (no) 2003-06-19
IL154984A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
DK1501819T3 (da) Østrogenreceptormodulatorer
ATE524170T1 (de) Östrogenrezeptor modulatoren
HUP0303563A2 (hu) Ösztrogén receptor modulátorok
WO2002091993A3 (en) Estrogen receptor modulators
TW200631933A (en) Estrogen receptor modulators
ATE329904T1 (de) Östrogenrezeptormodulatoren
WO2006062876A3 (en) Estrogen receptor modulators
WO2004073612A3 (en) Estrogen receptor modulators
WO2004091488A3 (en) Estrogen receptor modulators
WO2006081152A3 (en) Estrogen receptor modulators
WO2002032373A3 (en) Estrogen receptor modulators
ATE517871T1 (de) Östrogenrezeptormodulatoren
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
WO2004089313A3 (en) Novel olanzapine forms and related methods of treatment
AR039282A1 (es) Moduladores de receptores de estrogeno
WO2005097141A3 (en) Estrogen receptor modulators
WO2004073610A3 (en) Estrogen receptor modulators
ATE301629T1 (de) Estrogenrezeptorliganden und verfahren
WO2002058639A3 (en) Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2008100560A3 (en) Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
WO2004026887A3 (en) Estrogen receptor modulators
WO2008057309A3 (en) Estrogen receptor modulators
WO2002043572A3 (en) Erythropoietin and erythropoietin receptor expression in human cancer
DOP2002000384A (es) Moduladores de receptores estrogenicos.
DOP2005000224A (es) Moduladores de los receptores de estrogeno